BR9814698A - Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase - Google Patents

Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase

Info

Publication number
BR9814698A
BR9814698A BR9814698-0A BR9814698A BR9814698A BR 9814698 A BR9814698 A BR 9814698A BR 9814698 A BR9814698 A BR 9814698A BR 9814698 A BR9814698 A BR 9814698A
Authority
BR
Brazil
Prior art keywords
inhibitor
combination
aldose reductase
glycogen phosphorylase
glycogen
Prior art date
Application number
BR9814698-0A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9814698A publication Critical patent/BR9814698A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Noise Elimination (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE UM INIBIDOR DA ALDOSE-REDUTASE COM UM INIBIDOR DO GLICOGêNIO-FOSFORILASE"<D>. Composições e métodos de combinações farmacêuticas incluindo inibidores de aldose-redutase e inibidores de glicogênio-fosforilase. As composições e métodos são úteis para o tratamento de condições de resistência à insulina, tais como diabetes e na redução de lesão dos tecidos devida a isquemia.
BR9814698-0A 1997-11-21 1998-11-02 Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase BR9814698A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
BR9814698A true BR9814698A (pt) 2000-10-03

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814698-0A BR9814698A (pt) 1997-11-21 1998-11-02 Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase

Country Status (38)

Country Link
EP (1) EP1032424B9 (pt)
JP (1) JP2002504478A (pt)
KR (2) KR20010032304A (pt)
CN (1) CN1279617A (pt)
AP (1) AP911A (pt)
AR (1) AR016423A1 (pt)
AT (1) ATE205403T1 (pt)
AU (1) AU733304B2 (pt)
BG (1) BG104435A (pt)
BR (1) BR9814698A (pt)
CA (1) CA2310069A1 (pt)
DE (1) DE69801680T2 (pt)
DK (1) DK1032424T3 (pt)
DZ (1) DZ2656A1 (pt)
EA (1) EA002365B1 (pt)
ES (1) ES2161548T3 (pt)
GR (1) GR3037071T3 (pt)
GT (1) GT199800166A (pt)
HR (1) HRP20000327A2 (pt)
HU (1) HUP0100272A3 (pt)
ID (1) ID24524A (pt)
IL (1) IL135713A0 (pt)
IS (1) IS5453A (pt)
MA (1) MA26568A1 (pt)
NO (1) NO20002164L (pt)
OA (1) OA11379A (pt)
PA (1) PA8462301A1 (pt)
PE (1) PE135399A1 (pt)
PL (1) PL340643A1 (pt)
PT (1) PT1032424E (pt)
SK (1) SK7222000A3 (pt)
TN (1) TNSN98211A1 (pt)
TR (1) TR200001451T2 (pt)
UA (1) UA57811C2 (pt)
UY (1) UY25258A1 (pt)
WO (1) WO1999026659A1 (pt)
YU (1) YU30700A (pt)
ZA (1) ZA9810636B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DE122008000018I1 (de) 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2545311C (en) 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
JP2008505975A (ja) 2004-07-12 2008-02-28 フェノミックス コーポレーション 制約されたシアノ化合物
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
EP2144902B1 (en) 2007-05-04 2012-05-16 Bristol-Myers Squibb Company [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
JP2010526146A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
EP2170864B1 (en) 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
PL2665477T3 (pl) 2011-01-20 2016-05-31 Bionevia Pharmaceuticals Inc Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
ATE206702T1 (de) * 1995-06-06 2001-10-15 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren

Also Published As

Publication number Publication date
MA26568A1 (fr) 2004-12-20
PE135399A1 (es) 2000-01-15
AU9555898A (en) 1999-06-15
UA57811C2 (uk) 2003-07-15
CN1279617A (zh) 2001-01-10
PA8462301A1 (es) 2000-05-24
TR200001451T2 (tr) 2002-06-21
JP2002504478A (ja) 2002-02-12
NO20002164L (no) 2000-07-19
EP1032424A1 (en) 2000-09-06
KR100661214B1 (ko) 2006-12-26
DE69801680T2 (de) 2002-02-07
AU733304B2 (en) 2001-05-10
IS5453A (is) 2000-04-14
CA2310069A1 (en) 1999-06-03
AP9801401A0 (en) 1998-12-31
GT199800166A (es) 2000-04-19
HRP20000327A2 (en) 2001-02-28
WO1999026659A1 (en) 1999-06-03
UY25258A1 (es) 2000-12-29
IL135713A0 (en) 2001-05-20
AP911A (en) 2000-12-07
PL340643A1 (en) 2001-02-12
ID24524A (id) 2000-07-20
GR3037071T3 (en) 2002-01-31
OA11379A (en) 2004-01-28
PT1032424E (pt) 2001-12-28
HUP0100272A3 (en) 2002-11-28
EP1032424B9 (en) 2004-10-06
NO20002164D0 (no) 2000-04-27
DZ2656A1 (fr) 2003-03-22
ES2161548T3 (es) 2001-12-01
TNSN98211A1 (fr) 2005-03-15
EA200000433A1 (ru) 2000-12-25
YU30700A (sh) 2002-12-10
ZA9810636B (en) 2000-05-22
AR016423A1 (es) 2001-07-04
EP1032424B1 (en) 2001-09-12
EA002365B1 (ru) 2002-04-25
KR20010032304A (ko) 2001-04-16
BG104435A (bg) 2001-01-31
ATE205403T1 (de) 2001-09-15
DE69801680D1 (de) 2001-10-18
DK1032424T3 (da) 2001-11-19
SK7222000A3 (en) 2001-09-11
HUP0100272A2 (hu) 2001-06-28
KR20010032300A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
BR0317822A (pt) Composição fluoroquìmica
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
WO2004088233A3 (en) Thermal surgical procedures and compositions
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
CU23432B6 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
BR9710899A (pt) Composição compreendendo mupirocin e clorohexidina.
NO20000045L (no) Farmasøytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor
ATE444083T1 (de) Selektives targeting von apoptotischen zellen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.